Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox

Choi, 2010, LPA receptors: subtypes and biological actions, Annu Rev Pharmacol Toxicol, 50, 157, 10.1146/annurev.pharmtox.010909.105753 McIntyre, 2003, Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist, Proc Natl Acad Sci U S A, 100, 131, 10.1073/pnas.0135855100 Parrill, 2013, Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions, Biochim Biophys Acta, 1831, 2, 10.1016/j.bbalip.2012.09.002 Hecht, 1996, Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex, J Cell Biol, 135, 1071, 10.1083/jcb.135.4.1071 An, 1998, Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid, J Biol Chem, 273, 7906, 10.1074/jbc.273.14.7906 Bandoh, 1999, Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid, J Biol Chem, 274, 27776, 10.1074/jbc.274.39.27776 Noguchi, 2003, Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family, J Biol Chem, 278, 25600, 10.1074/jbc.M302648200 Lee, 2006, GPR92 as a New G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5, J Biol Chem, 281, 23589, 10.1074/jbc.M603670200 Yanagida, 2009, Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6, J Biol Chem, 284, 17731, 10.1074/jbc.M808506200 Yanagida, 2011, Non-Edg family LPA receptors: the cutting edge of LPA research, J Biochem, 150, 223, 10.1093/jb/mvr087 Gerrard, 1979, Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux, Am J Pathol, 96, 423 Tokumura, 1980, Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregant rats, Arch Int Pharmacodyn Ther, 245, 74 Tokumura, 1978, Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species, Lipids, 13, 572, 10.1007/BF02533598 Van Corven, 1992, Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts dependence on acyl-chain length and inhibition by suramin, Biochem J, 281, 163, 10.1042/bj2810163 Hao, 2007, Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA1, p42 and p38α, Biochim Biophys Acta, 1771, 883, 10.1016/j.bbalip.2007.04.010 Tigyi, 2010, Aiming drug discovery at lysophosphatidic acid targets, Br J Pharmacol, 161, 241, 10.1111/j.1476-5381.2010.00815.x Kihara, 2014, Lysophospholipid receptor nomenclature review: IUPHAR review 8, Br J Pharmacol, 171, 3575, 10.1111/bph.12678 Tokumura, 1995, A family of phospholipid autacoids: occurrence, metabolism and bioactions, Prog Lipid Res, 34, 151, 10.1016/0163-7827(95)00001-G Tokumura, 2002, Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase, J Biol Chem, 10.1074/jbc.M205623200 Umezu-Goto, 2002, Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production, J Cell Biol, 158, 227, 10.1083/jcb.200204026 Houben, 2011, Autotaxin and LPA receptor signaling in cancer, Cancer Metastasis Rev, 30, 557, 10.1007/s10555-011-9319-7 Okudaira, 2010, Biological roles of lysophosphatidic acid signaling through its production by autotaxin, Biochimie, 92, 698, 10.1016/j.biochi.2010.04.015 Akira, 1986, Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma, Biochim Biophys Acta, 875, 31, 10.1016/0005-2760(86)90007-X Tokumura, 1978, Identification of vasopressor phospholipid in crude soybean lecithin, Lipids, 13, 468, 10.1007/BF02533615 Tokumura, 1981, Lysophosphatidic acid-induced aggregation of human and feline platelets – structure–activity relationship, Biochem Biophys Res Commun, 99, 391, 10.1016/0006-291X(81)91758-7 Tokumura, 1981, Cardiovascular effects of lysophosphatidic acid and its structural analogs in rats, J Pharmacol Exp Ther, 219, 219 Tokumura, 1985, Effects of lysophosphatidic acids and their structural analogs on arterial blood-pressure of cats, Drug Res, 35–1, 587 Ishii, 2004, Lysophospholipid receptors: signaling and biology, Annu Rev Biochem, 73, 321, 10.1146/annurev.biochem.73.011303.073731 Contos, 2000, Lysophosphatidic acid receptors, Mol Pharmacol, 58, 1188, 10.1124/mol.58.6.1188 Fukushima, 2001, Lysophospholipid receptors, Annu Rev Pharmacol Toxicol, 41, 507, 10.1146/annurev.pharmtox.41.1.507 Mukherjee, 2013 Hama, 2004, Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1, J Biol Chem, 279, 17634, 10.1074/jbc.M313927200 Boucharaba, 2006, The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases, Proc Natl Acad Sci U S A, 103, 9643, 10.1073/pnas.0600979103 Komachi, 2012, Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo, Cancer Sci, 103, 1099, 10.1111/j.1349-7006.2012.02246.x Murph, 2007, Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells, Mol Cancer Res, 5, 1201, 10.1158/1541-7786.MCR-06-0338 Guo, 2006, Expression and function of lysophosphatidic acid LPA(1) receptor in prostate cancer cells, Endocrinology, 147, 4883, 10.1210/en.2005-1635 Pradere, 2007, LPA1 receptor activation promotes renal interstitial fibrosis, J Am Soc Nephrol, 18, 3110, 10.1681/ASN.2007020196 Tager, 2008, The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak, Nat Med, 14, 45, 10.1038/nm1685 Swaney, 2010, A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model, Br J Pharmacol, 160, 1699, 10.1111/j.1476-5381.2010.00828.x Swaney, 2011, Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist, J Pharmacol Exp Ther, 336, 693, 10.1124/jpet.110.175901 Castelino, 2011, Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma, Arthritis Rheum, 63, 1405, 10.1002/art.30262 Roberts, 2005, Neurochemical changes in LPA(1) receptor deficient mice – a putative model of schizophrenia, Neurochem Res, 30, 371, 10.1007/s11064-005-2611-6 Anliker, 2013, Lysophosphatidic acid (LPA) and its receptor, LPA(1), influence embryonic schwann cell migration, myelination, and cell-to-axon segregation, Glia, 61, 2009, 10.1002/glia.22572 Balood, 2014, Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis, Hum Immunol, 75, 411, 10.1016/j.humimm.2014.02.021 Nieto-Posadas, 2012, Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site, Nat Chem Biol, 8, 78, 10.1038/nchembio.712 Inoue, 2004, Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling, Nat Med, 10, 712, 10.1038/nm1060 Ueda, 2006, Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms, Pharmacol Ther, 109, 57, 10.1016/j.pharmthera.2005.06.003 Inoue, 2008, Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain, Mol Pain, 4, 6, 10.1186/1744-8069-4-6 Kanan, 2008 Nakade, 2002 Miyabe, 2013, Necessity of lysophosphatidic acid receptor 1 for development of arthritis, Arthritis Rheum, 65, 2037, 10.1002/art.37991 Karagiosis, 2007, Lysophosphatidic acid induces osteocyte dendrite outgrowth, Biochem Biophys Res Commun, 357, 194, 10.1016/j.bbrc.2007.03.121 Liu, 2010, LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4, J Cell Biochem, 109, 794 Gennero, 2011, Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass, Bone, 49, 395, 10.1016/j.bone.2011.04.018 Mirendil, 2013 Goetzl, 1999, Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax, J Immunol, 162, 2049, 10.4049/jimmunol.162.4.2049 Zheng, 2000, Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes, FASEB J, 14, 2387, 10.1096/fj.00-0492fje Zheng, 2001, Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane, J Immunol, 166, 2317, 10.4049/jimmunol.166.4.2317 Deng, 2002, Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis, Gastroenterology, 123, 206, 10.1053/gast.2002.34209 Holmstrom, 2010, Non-transactivational, dual pathways for LPA-induced Erk1/2 activation in primary cultures of brown pre-adipocytes, Exp Cell Res, 316, 2664, 10.1016/j.yexcr.2010.05.029 Goetzl, 1999, Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer, Cancer Res, 59, 5370 Yun, 2005, LPA(2) receptor mediates mitogenic signals in human colon cancer cells, Am J Physiol Cell Physiol, 289, C2, 10.1152/ajpcell.00610.2004 Yu, 2008, Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells, J Natl Cancer Inst, 100, 1630, 10.1093/jnci/djn378 Huang, 2004, Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA(2)), Oncogene, 23, 122, 10.1038/sj.onc.1206986 Huang, 2004, Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2), Oncogene, 23, 122, 10.1038/sj.onc.1206986 So, 2004, Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8, Gynecol Oncol, 95, 314, 10.1016/j.ygyno.2004.08.001 So, 2005, LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2), Gynecol Oncol, 97, 870, 10.1016/j.ygyno.2005.03.004 Hope, 2009, LPA receptor 2 mediates LPA-induced endometrial cancer invasion, Gynecol Oncol, 112, 215, 10.1016/j.ygyno.2008.09.019 Lin, 2010, The absence of LPA receptor 2 reduces the tumorigenesis by Apc(Min) mutation in the intestine, Am J Physiol Renal Physiol, 299, G1128 Kiss, 2013, Mitigation of radiation injury by selective stimulation of the LPA2 receptor, Biochim Biophys Acta, 1831, 117, 10.1016/j.bbalip.2012.08.020 Ye, 2005, LPA(3)-mediated lysophosphatidic acid signalling in embryo implantation and spacing, Nature, 435, 104, 10.1038/nature03505 Chan, 2007, LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA), J Leukoc Biol, 82, 1193, 10.1189/jlb.0407221 Dey, 2004, Molecular cues to implantation, Endocr Rev, 25, 341, 10.1210/er.2003-0020 Rother, 2003, Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques, Circulation, 108, 741, 10.1161/01.CIR.0000083715.37658.C4 Ma, 2009, Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain, Mol Pain, 5, 64, 10.1186/1744-8069-5-64 Lee, 2008, Role of LPA(4)/p2y9/GPR23 in negative regulation of cell motility, Mol Biol Cell, 19, 5435, 10.1091/mbc.e08-03-0316 Khandoga, 2008, Lysophosphatidic acid-induced platelet shape change revealed through LPA(1–5) receptor-selective probes and albumin, Platelets, 19, 415, 10.1080/09537100802220468 Pamuklar, 2008, Individual heterogeneity in platelet response to lysophosphatidic acid – evidence for a novel inhibitory pathway, Arterioscler Thromb Vasc Biol, 28, 555, 10.1161/ATVBAHA.107.151837 Yanagida, 2007, LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line, J Biol Chem, 282, 5814, 10.1074/jbc.M610767200 Mansell, 2010, The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces, Biomaterials, 31, 199, 10.1016/j.biomaterials.2009.09.035 Kotarsky, 2006, Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes, J Pharmacol Exp Ther, 318, 619, 10.1124/jpet.105.098848 Lee, 2006, GPR92 as a new G(12/13)- and G(q)-coupled lysophosphatidic acid receptor that increases cAMP, LPA(5), J Biol Chem, 281, 23589, 10.1074/jbc.M603670200 Lundequist, 2011, LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1 beta release, PLoS ONE, 6, e18192-e, 10.1371/journal.pone.0018192 Oh, 2008, Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92, J Biol Chem, 283, 21054, 10.1074/jbc.M708908200 Lin, 2012, Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain, J Biol Chem, 287, 17608, 10.1074/jbc.M111.330183 Kinloch, 2005, New targets for neuropathic pain therapeutics, Expert Opin Ther Targets, 9, 685, 10.1517/14728222.9.4.685 Khandoga, 2011, GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques, Cardiovasc Res, 90, 157, 10.1093/cvr/cvq369 Lin, 2010, Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2, Gastroenterology, 138, 649, 10.1053/j.gastro.2009.09.055 Shimomura, 2008, Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair, Nature Genet, 40, 335, 10.1038/ng.100 Kano, 2008, LPA and its analogs-attractive tools for elucidation of LPA biology and drug development, Curr Med Chem, 15, 2122, 10.2174/092986708785747562 Prestwich, 2008, Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer, Biochim Biophys Acta, 1781, 588, 10.1016/j.bbalip.2008.03.008 Zhang, 2009, Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo, Cancer Res, 69, 5441, 10.1158/0008-5472.CAN-09-0302 Lynch Kevin, 2002, Structure–activity relationships of lysophosphatidic acid analogs, Biochim Biophys Acta, 1582, 289, 10.1016/S1388-1981(02)00183-X Heise, 2001, Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist, Mol Pharmacol, 60, 1173, 10.1124/mol.60.6.1173 Prestwich, 2005, New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors, Biochem Soc Trans, 33, 1357, 10.1042/BST0331357 East, 2011, Development of a phosphatase-resistant, l-tyrosine derived LPA1/LPA3 dual antagonist, MedChemComm, 2, 325, 10.1039/c0md00273a Lipinski, 2004, Lead- and drug-like compounds: the rule-of-five revolution, Drug Discov Today Technol, 1, 337, 10.1016/j.ddtec.2004.11.007 Budd, 2013, Development of lysophosphatidic acid pathway modulators as therapies for fibrosis, Future Med Chem, 5, 1935, 10.4155/fmc.13.154 Parrill, 2014, Design of anticancer lysophosphatidic acid agonists and antagonists, Future Med Chem, 6, 871, 10.4155/fmc.14.52 Ueno, 2001 Ohta, 2003, Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors, Mol Pharmacol, 64, 994, 10.1124/mol.64.4.994 Kimura, 2011, P2y5/LPA6 attenuates LPA1-mediated VE-cadherin translocation and cell–cell dissociation through G12/13 protein–Src–Rap1, Cardiovasc Res, 92, 149, 10.1093/cvr/cvr154 David, 2012, Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis, Int J Oncol, 40, 1133, 10.3892/ijo.2011.1309 Sato, 2012, Synthesis and biological evaluation of optically active Ki16425, Bioorg Med Chem Lett, 22, 4323, 10.1016/j.bmcl.2012.05.012 Yamamoto, 2007, Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists, Bioorg Med Chem Lett, 17, 3736, 10.1016/j.bmcl.2007.04.024 Ajinomoto’s LPA1 antagonist for fibrotic diseases. In: M PM, editor. American chemical society – 243rd national meeting and exposition (Part II) San Diego, CA, USA; 2011. Structure identified in a non-peer reviewed printed source. Thomson Reuters Cortellis. Erikson, 1999 Brittain, 2011 Brittain, 2012 Hutchinson, 2011 Hutchinson, 2011 Seiders, 2011 Santos, 2013 An, 2012 Gabriel, 2013 Gabriel, 2013 Gabriel, 2013 Qian, 2012, Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts, J Med Chem, 55, 7920, 10.1021/jm301022v Budd, 2014 Sidduri, 2014, Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists, Bioorg Med Chem Lett, 24, 4450, 10.1016/j.bmcl.2014.08.001 Tellew, 2012 Buckman, 2013 Discovery and anti-fibrotic activity of novel antagonists of lysophosphatidic acid receptor 1 (LPAR1). In: 2014 American thoracic society international conference (ATS). San Diego, California, US; 2014. Shankar, 2003 Terakado, 2004 Tanaka, 2005 Kawaminami, 2011 Kawaminami, 2012 Schaefer, 2009 Pernerstorfer, 2011 <http://clinicaltrials.gov/show/NCT01651143>, [accessed 2014-12-10]. Dinesh Khanna CPD, Alexandre Jagerschmidt, Martine Jasson, Oliver Distler, Yannick Allanore. SAR100842, an antagonist of lysophaphatidic acid receptor 1, as a potential treatment for patients with systemic sclerosis: results from a phase 2a study. In: 78th American college of rheumatology annual scientific meeting. Boston, Massachusetts: USA; 2014. 31-Jul-2014, Solid sales and business EPS(1) growth at CER in Q2 2014. 28-Oct-2010, Resilient sales and business EPS1 in Q3 2010 Sanofi-Aventis, Source ID: 1142785. <http://www.sbir.gov/sbirsearch/detail/400200>, [accessed 2014-12-10]. Beck, 2008, Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents, Bioorg Med Chem Lett, 18, 1037, 10.1016/j.bmcl.2007.12.024 Schiemann, 2012 Schiemann, 2013 Staehle, 2013 Kiss, 2012, Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions, Mol Pharmacol, 82, 1162, 10.1124/mol.112.079699 Patil, 2014 Patil, 2014, Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor, J Med Chem, 57, 7136, 10.1021/jm5007116 <https://www.sbir.gov/sbirsearch/detail/295496>, [accessed 2014-12-10]. <https://www.medicalcountermeasures.gov/newsroom/2011/protect-against-radiation.aspx>, [accessed 2014-12-10]. Fells, 2008, Identification of non-lipid LPA3 antagonists by virtual screening, Bioorg Med Chem Lett, 16, 6207, 10.1016/j.bmc.2008.04.035 Fells, 2009, Structure-based drug design identifies novel LPA3 antagonists, Bioorg Med Chem Lett, 17, 7457, 10.1016/j.bmc.2009.09.022 Solow-Cordero, 2005 Wong, 2010, Strategy for the identification of GPR23/LPA4 receptor agonists and inverse agonists, Assay Drug Dev Technol, 8, 459, 10.1089/adt.2009.0261 Kozian, 2012, Selective non-lipid modulator of LPA5 activity in human platelets, Bioorg Med Chem Lett, 22, 5239, 10.1016/j.bmcl.2012.06.057 Nazare, 2013 Nazare, 2013 Nazare, 2013 Choi, 2012 Sardar, 2002, Molecular basis for lysophosphatidic acid receptor antagonist selectivity, Biochim Biophys Acta, 1582, 309, 10.1016/S1388-1981(02)00185-3 Fujiwara, 2005, Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells, J Biol Chem, 280, 35038, 10.1074/jbc.M504351200 Li, 2009, Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA4/p2y9/GPR23 receptor: a homology modeling study, J Mol Graph Model, 28, 70, 10.1016/j.jmgm.2009.04.004 <http://www.nature.com/nature/focus/gpcrs/>, [accessed 2014-12-10].